Coronary artery disease occurring with protease inhibitor therapy

被引：26

作者：

Sullivan, AK ^{[1
]}

Nelson, MR ^{[1
]}

Moyle, GJ ^{[1
]}

Newell, AM ^{[1
]}

Feher, MD ^{[1
]}

Gazzard, BG ^{[1
]}

机构：

[1] Chelsea & Westminster Hosp, St Stephens Ctr, Imperial Coll, Sch Med, London SW10 9NH, England

来源：

INTERNATIONAL JOURNAL OF STD & AIDS | 1998年 / 9卷 / 11期

关键词：

coronary artery disease; protease inhibitors; hyperlipidaemia;

D O I：

10.1258/0956462981921251

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Protease inhibitors are increasingly recognized as causing significant metabolic abnormalities including hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, diabetes, and lipodystrophy(1,2). Considerable concern has been generated by recent reports(3) of premature coronary artery disease occurring in HIV-1 infected patients on protease inhibitor containing regimens.

引用

页码：711 / 712

页数：2

共 4 条

[1] A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors [J].

Carr, A ;

Samaras, K ;

Burton, S ;

Law, M ;

Freund, J ;

Chisholm, DJ ;

Cooper, DA .

AIDS, 1998, 12 (07) :F51-F58

[2] Severe premature coronary artery disease with protease inhibitors [J].

Henry, K ;

Melroe, H ;

Huebsch, J ;

Hermundson, J ;

Levine, C ;

Swensen, L ;

Daley, J .

LANCET, 1998, 351 (9112) :1328-1328

[3]

SHAPER AG, 1984, BRIT HEART J, V51, P595, DOI 10.1136/hrt.51.6.595

[4]

Sullivan AK, 1997, AIDS, V11, P938

← 1 →